PapersPMID:27269392
The effect of Astragalus as an adjuvant treatment in type 2 diabetes mellitus: A (preliminary) meta-analysis.
What moved
1 findingHow to read these marks →- Decreases glycated haemoglobin (HbA1c)
very limited
“Although AAD treatment significantly reduced levels of glycated hemoglobin A1c (HbA1c) (WMD=-1.77, 95% CI=-3.06 to -0.47, P=0.007, I(2)=90.8%), AI treatment failed to show significant efficacy (WMD=-0.28, 95% CI=-0.63 to 0.06, P=0.102, I(2)=83.8%).”
- Study
- meta-analysis
- Effect
- −1.77 mean difference, 95% CI −3.06 to −0.47
- Population
- Adults with type 2 diabetes mellitus; pooled controlled trials of Astragalus aqueous decoction as adjuvant treatment versus control group (13 studies, 1054 participants across both Astragalus subgroups)
Study record
- Design
- meta-analysis
- Species
- human
- Population
- patients with type 2 diabetes mellitus (T2DM)
- Participants
- 1,054
- Comparator
- no treatment / not stated in the paper
- Duration
- not reported
- Endpoints measured
- 8